Market Overview

vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Share:

Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented
during Oral Session

Subgroup Data Discussing the Effect of Azeliragon in Patients with
Dementia and Diabetes to be Presented during Poster Session

vTv
Therapeutics Inc.
(NASDAQ:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally administered
treatments for Alzheimer's disease and diabetes, today announced that it
will deliver an oral presentation and present a poster at the 11th
Clinical Trials on Alzheimer's Disease (CTAD) conference on October
24-27, 2018 in Barcelona, Spain.

The oral presentation will detail the results from the phase 3 STEADFAST
study of azeliragon in patients with mild Alzheimer's disease. Details
of the oral presentation are listed below:

Oral Presentation Title: "Safety and efficacy results from the
phase 3, multicenter, 18-month STEADFAST trial of azeliragon in patients
with mild Alzheimer's disease"

Date and Time: Fri., Oct.
26, 2018 at 3 p.m. CEST (9 a.m. EST)

In addition, a subgroup analysis from the company's STEADFAST trial will
be presented as a poster. Details of the poster presentation are listed
below:

Late-Breaking Poster Title: "Is RAGE the missing link between
diabetes and dementia? Results from a subgroup analysis of the STEADFAST
trial"

Poster Number: LBP18
Category:
Clinical Trials: Results
Date and Time: Wed., Oct. 24, 2018
(3 p.m. CEST) through Sat., Oct. 27, 2018 (3 p.m. CEST)

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer's disease and diabetes as well as treatment of
inflammatory disorders.

About STEADFAST

The STEADFAST study, two independent and identical randomized,
double-blind, placebo-controlled Phase 3 trials (Part A and Part B), was
designed to investigate the safety and efficacy of azeliragon as a
potential treatment for patients with mild Alzheimer's disease. The
18-month study targeted enrollment of 800 patients (400 in each trial).
The first trial enrolled patients in the United States and Canada who
had a clinical diagnosis of mild Alzheimer's disease and an MRI
consistent with this diagnosis. Enrollment of the second trial included
study sites in the United Kingdom, Ireland, Australia, New
Zealand and South Africa. In April 2018, results were announced that the
Part A Study failed to meet either co-primary endpoint and clinical
trials involving azeliragon, including the Part B Study and the
open-label extension study were terminated, although the majority of
patients in the Part B Study had at least 12 months' worth of data at
the time of closure. In June 2018, topline efficacy results from the
Part B Study were announced showing that the study also failed to meet
either of the co-primary endpoints.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
"anticipate," "believe," "could," "estimate," "expect," "intend," "may,"
"plan," "potential," "predict," "project," "should," "target," "will,"
"would" and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading "Risk Factors" in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.

View Comments and Join the Discussion!